Loading…
Nasus Pharma Ltd. is projected to decline to $2.74 by 2027, a -9% move from its current price of $3.02. NSRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.86 | $3.02 | $3.19 | +0.04% |
| May 30 | $2.79 | $3.02 | $3.27 | +0.09% |
| May 31 | $2.75 | $3.02 | $3.33 | +0.13% |
| Jun 1 | $2.71 | $3.03 | $3.38 | +0.18% |
| Jun 2 | $2.67 | $3.03 | $3.43 | +0.22% |
| Jun 3 | $2.64 | $3.03 | $3.47 | +0.26% |
| Jun 4 | $2.62 | $3.03 | $3.51 | +0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.62 | $3.03 | $3.51 | +0.31% |
| Week 2 | $2.47 | $3.04 | $3.74 | +0.62% |
| Week 3 | $2.36 | $3.05 | $3.93 | +0.93% |
| Week 4 | $2.28 | $3.06 | $4.10 | +1.24% |
| Week 5 | $2.21 | $3.07 | $4.26 | +1.55% |
| Week 6 | $2.15 | $3.08 | $4.41 | +1.86% |
| Week 7 | $2.09 | $3.09 | $4.55 | +2.18% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose.
Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Nasus Pharma Ltd. (NSRX) is a healthcare stock listed with a current price of $2.90 and a market cap of $33.96M. It ranks 4760 by market capitalization among listed assets.
The stock trades within a 30-day range of $1.99 to $4.22, with a near-term momentum indicated by an RSI of 50 and a 50-day simple moving average of $2.76.
Its price outlook combines neutral and bullish signals across the forecast horizon, with a measured level of volatility reflected in an annualized volatility of 100%.
A major floor 55.0% below — a decisive break under it would weaken the trend.
The nearest floor, 26.8% below — buyers have tended to step in here.
The nearest ceiling, 28.8% above — a clean break opens room to run.
A major ceiling 133.4% above — clearing it would confirm fresh momentum.
Key NSRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NSRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.87 | Buy | $2.90 | Buy |
| MA 10 | $2.87 | Buy | $2.90 | Buy |
| MA 20 | $2.90 | Buy | $2.90 | Buy |
| MA 50 | $2.72 | Buy | $3.19 | Sell |
| MA 100 | $4.25 | Sell | $4.05 | Sell |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.48 | Neutral |
| Stoch RSI (14) | 64.41 | Neutral |
| CCI (20) | 52.08 | Neutral |
| Williams %R (14) | -53.62 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -4.13 | Sell |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 46.38 | Neutral |
| TRIX (15) | 0.00 | Buy |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 55.54 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 2.92 | Buy |
| ADX (14) | 9.04 | Neutral |
| ATR (14) | 0.15 | Info |
The near-term technical picture is neutral, as reflected by an RSI of 50. Price action remains near the 50-day moving average, which sits at $2.76, providing a checkpoint near the current price.
Key support is at $2.21 and resistance at $3.89, outlining a defined range for near-term moves. The 30-day price range spans from $1.99 to $4.22, indicating established short-term variability.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.01 | $3.02 | $4.02 | 0% | Neutral | |
| $1.78 | $2.74 | $4.55 | -9% | Neutral | |
| $1.34 | $2.27 | $4.10 | -25% | Bearish | |
| $1.59 | $2.94 | $5.62 | -3% | Neutral | |
| $1.82 | $3.66 | $7.35 | +21% | Bullish | |
| $1.59 | $3.47 | $7.29 | +15% | Neutral | |
| $1.71 | $3.79 | $8.27 | +26% | Bullish | |
| $1.55 | $3.45 | $7.78 | +14% | Neutral | |
| $1.31 | $2.90 | $6.68 | -4% | Neutral | |
| $1.47 | $3.27 | $7.51 | +8% | Neutral | |
| $2.02 | $4.49 | $10.32 | +49% | Bullish | |
| $4.22 | $9.39 | $21.59 | +211% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.01 | $3.02 | $3.66 | +0.00% |
| June 2026 | $2.63 | $3.22 | $4.13 | +6.75% |
| July 2026 | $2.50 | $3.14 | $4.17 | -2.49% |
| August 2026 | $2.40 | $3.08 | $4.20 | -2.08% |
| September 2026 | $2.46 | $3.20 | $4.45 | +3.87% |
| October 2026 | $2.37 | $3.13 | $4.44 | -2.14% |
| November 2026 | $2.12 | $2.84 | $4.10 | -9.19% |
| December 2026 | $2.02 | $2.74 | $4.02 | -3.45% |
Click any year to see its month-by-month NSRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Nasus Pharma Ltd.'s 2026 outlook centres on $3.02, within a $2.01 to $4.02 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, NSRX could reach as high as $4.55, with a base case around $2.74 and support toward $1.78 — roughly -9% from $3.02. A consolidation phase looks the most probable path here.
Expect NSRX to range from $1.34 to $4.10 through 2028. The $2.27 average target implies a -25% move from current prices. That is -17% versus the projected 2027 average. A cyclical pullback looks likely — prices rarely move in a straight line.
The NSRX price prediction for 2029 points to an average of $2.94 (low $1.59, high $5.62) — a potential decline of -3% on today's $3.02. A consolidation phase looks the most probable path here.
In 2030, NSRX is projected to trade between $1.82 and $7.35, averaging $3.66 — a potential gain of +21% from today's $3.02. That is up +24% on the projected 2029 average. Momentum favours further upside here.
Nasus Pharma Ltd.'s 2031 outlook centres on $3.47, within a $1.59 to $7.29 range. That is -5% versus the projected 2030 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, NSRX could reach as high as $8.27, with a base case around $3.79 and support toward $1.71 — roughly +26% from $3.02. Momentum favours further upside here.
Expect NSRX to range from $1.55 to $7.78 through 2033. The $3.45 average target implies a +14% move from current prices. That is -9% versus the projected 2032 average. A consolidation phase looks the most probable path here.
The NSRX price prediction for 2034 points to an average of $2.90 (low $1.31, high $6.68) — a potential decline of -4% on today's $3.02. Price action looks broadly range-bound.
In 2035, NSRX is projected to trade between $1.47 and $7.51, averaging $3.27 — a potential gain of +8% from today's $3.02. That is up +12% on the projected 2034 average. A consolidation phase looks the most probable path here.
Nasus Pharma Ltd.'s 2040 outlook centres on $4.49, within a $2.02 to $10.32 range. That is up +37% on the projected 2035 average. That marks a +49% change versus current levels. Momentum favours further upside here.
By 2050, NSRX could reach as high as $21.59, with a base case around $9.39 and support toward $4.22 — roughly +211% from $3.02. Buyers look set to stay in control over this stretch.
Investing $1,000 in NSRX today (≈ 331.125828 NSRX) could be worth
$3,108.89
+$2,108.89 (+211%) by 2050 · US Dollar
Based on the average projected NSRX price of $9.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NSRXwould be worth at today's price.
$1,000 invested in NSRX on Aug 13, 2025 (≈ 121.212121 NSRX) would be worth
$366.06
-$633.94 (-63.4%) today · 0.37× · US Dollar
Based on a NSRX entry price of $8.25 vs. today's $3.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.74 | $1,102.19 | +10.2% |
| 1 month ago | $3.18 | $949.69 | -5.0% |
| 3 months ago | $5.1 | $592.16 | -40.8% |
| 6 months ago | $7 | $431.43 | -56.9% |
| All time ago | $8.25 | $366.06 | -63.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NSRX forecast.
Our base-case forecast reaches $6.00 around 2050.
Implied market cap at $6.00: $70.26M
The multi-year forecast shows a path of gradual upside with varying yearly targets. In 2026, the average price is forecast at $2.90 with a min of $2.01 and a max of $3.88, yielding a 0% ROI and a neutral sentiment.
By 2030, the average is projected at $3.44 with a min of $1.71 and a max of $6.94, delivering an 18.7% ROI and a neutral sentiment.
In 2040, the forecast climbs to an average of $4.19 with a min of $1.88 and a max of $9.63, translating to a 44.3% ROI and a bullish sentiment. By 2050, the average reaches $8.82 with a min of $3.97 and a max of $20.30, equating to a 204.3% ROI and a bullish outlook.
The forecast also highlights intermittent shifts in sentiment and periods of higher volatility, with bullish signals appearing in 2032 (avg $3.63, max $7.94, ROI 25.3%) and sustained bullishness into 2040 and 2050. These figures are estimates and should be considered within the inherent uncertainty of forward-looking projections.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $3.44, with a min of $1.71 and a max of $6.94, and an ROI of 18.7%. The sentiment is neutral.
The outlook shows mixed timing: near-term forecasts for 2026–2029 are neutral to bearish, while longer-term forecasts for 2030, 2040, and 2050 indicate higher average prices and positive ROIs (18.7%, 44.3%, and 204.3%, respectively). These are estimates and not guarantees.
Yes. The forecast for 2032 lists a max of $7.94, indicating the possibility of reaching that level in a future year.
Current price is $2.90. The 30-day range is $1.99 to $4.22.
By 2050, the average price is forecast at $8.82 with a max of $20.30 and a min of $3.97, corresponding to a 204.3% ROI and a bullish sentiment.
Nasus Pharma Ltd. Community Discussion
0Share your Nasus Pharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.